Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazosentan for vasospasm-related outcomes after aneurysmal subarachnoid hemorrhage treated by endovascular coiling
2008-006785-29Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clazosentan in subarachnoid hemorrhage (SAH) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks. Started Mar 2009; status: terminated.
02
Drugs
clazosentan
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2008-006785-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006785-29.